86 citations
,
July 2002 in “Clinical and Experimental Dermatology”
This review discusses female pattern hairloss, emphasizing its complex causes and the limited treatment options available, and reports no new clinical results.
29 citations
,
January 1993 in “Dermatologic Clinics”
This paper reviews diffuse androgen-dependent alopecia and chronic telogen effluvium in women, highlighting diagnostic challenges and management issues, but reports no new clinical findings; the authors suggest effective treatments are available.
5 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes”
This study found that nuclear androgen receptor levels varied among females with androgen-dependent dermatoses, being highest in hirsutism, which may suggest superior androgen stimulability compared to acne and androgenetic alopecia.
High sugar diets may worsen hairloss by increasing 5α-reductase activity and androgen levels, especially in women with PCOS. A low sugar diet might reduce scalp DHT levels, similar to finasteride, but genetics also significantly influence hairloss.
Promising hairloss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
GT20029 is a new hairloss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
A 25 year old male who has been using finasteride and dutasteride for two years to treat his hairloss, with no success. Other treatments such as oral minoxidil, topical anti-androgens, RU58841, latanoprost, topical estrogen, CB 03 01, microneedling, keto 2% shampoo, vitamin D, Omega 3, B vitamins and probiotics were discussed.
The conversation discusses hairloss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hairloss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
Frontline, gold standard treatment for combatting androgenic alopecia
Does hair strand thickness decrease in men with androgenic alopecia? Can finasteride help restore it?Androgenic alopecia thins hair strands by miniaturizing follicles. The pivotal finasteride trials (1,553 men, 1 mg/day, two years) report increased hair counts and improved assessed appearance, but they measured density, not the diameter of individual strands, so the effect on thickness itself is not established.
Alfatradiol: What does a form of estrogen have to do with hairloss in men?Alfatradiol (17α-estradiol) is a prescription topical hormone, licensed for androgenetic alopecia in Germany but not FDA-approved. The controlled trial evidence is in women, where it produced stabilisation rather than regrowth and was outperformed by minoxidil; no comparable placebo-controlled trial in men appears to have been published.